Skip to content

result of vitimelin tablet and vitimelin oil in vitiligo

Clinical study to evaluate the efficacy and safety of vitimelin tablet and vitimelin oil in vitiligo w.s.r. to shwitra

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033014
Enrollment
30
Registered
2021-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Vitimelin Tablet and Vitimelin oil: Oral - Vitimelin Tablet 1 tablet TID (500 mg each), Local application - Vitimelin oil- Two times on patches / affected area, after 10 min. of applica

Sponsors

DrVasishths Ayuremedies
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1-Children of either gender aged group between 10 - 16 years. 2- Children having classical sign and symptom and diagnosed as vitiligo / Shwitra. 3- Patient should be capable of obeying the instruction related to course of therapy.

Exclusion criteria

Exclusion criteria: 1- Children below 10 years and above 16 years of age. 2- Patches more than 30% of the body, Broad continuous irregular patches. 3- Children with albinism will be excluded. 4- White anesthetic spot which are characterized of leprosy. 5- Patches in genital area and only lip area are excluded from the study. 6- Patient not fulfilling the inclusion criteria. 7- Patient suffering from any other known systemic and chronic disease / Autoimmune disorder. 8- Patient not willing to give consent for participation in the Research study.

Design outcomes

Primary

MeasureTime frame
Changes in VASI score.Timepoint: 3 month

Secondary

MeasureTime frame
To evaluate the safety of trial drug (Vitimelin Tablet and Vitimelin Oil).Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Nisha Kumar Ojha

National Institute of Ayurveda, Jaipur

drrknagar@gmail.com9414062099

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026